SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2

Detalles Bibliográficos
Autores principales: Tan, Samuel, Douen, Aaron, Sukhoo-Pertab, Marc L., Siu, Wenchy, Mondal, Avilash, Toreli, Aleksandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Cardiology Foundation. Published by Elsevier Inc. 2023
Materias:
Prevention and Health Promotion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983040/
http://dx.doi.org/10.1016/S0735-1097(23)02235-0
_version_ 1784900460767870976
author Tan, Samuel
Douen, Aaron
Sukhoo-Pertab, Marc L.
Siu, Wenchy
Mondal, Avilash
Toreli, Aleksandre
author_facet Tan, Samuel
Douen, Aaron
Sukhoo-Pertab, Marc L.
Siu, Wenchy
Mondal, Avilash
Toreli, Aleksandre
author_sort Tan, Samuel
collection PubMed
description
format Online
Article
Text
id pubmed-9983040
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American College of Cardiology Foundation. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99830402023-03-03 SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2 Tan, Samuel Douen, Aaron Sukhoo-Pertab, Marc L. Siu, Wenchy Mondal, Avilash Toreli, Aleksandre J Am Coll Cardiol Prevention and Health Promotion American College of Cardiology Foundation. Published by Elsevier Inc. 2023-03-07 2023-03-03 /pmc/articles/PMC9983040/ http://dx.doi.org/10.1016/S0735-1097(23)02235-0 Text en © 2023 American College of Cardiology Foundation Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Prevention and Health Promotion
Tan, Samuel
Douen, Aaron
Sukhoo-Pertab, Marc L.
Siu, Wenchy
Mondal, Avilash
Toreli, Aleksandre
SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2
title SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2
title_full SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2
title_fullStr SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2
title_full_unstemmed SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2
title_short SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2
title_sort should beta blockers still be considered second line in patients with sars-cov-2
topic Prevention and Health Promotion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983040/
http://dx.doi.org/10.1016/S0735-1097(23)02235-0
work_keys_str_mv AT tansamuel shouldbetablockersstillbeconsideredsecondlineinpatientswithsarscov2
AT douenaaron shouldbetablockersstillbeconsideredsecondlineinpatientswithsarscov2
AT sukhoopertabmarcl shouldbetablockersstillbeconsideredsecondlineinpatientswithsarscov2
AT siuwenchy shouldbetablockersstillbeconsideredsecondlineinpatientswithsarscov2
AT mondalavilash shouldbetablockersstillbeconsideredsecondlineinpatientswithsarscov2
AT torelialeksandre shouldbetablockersstillbeconsideredsecondlineinpatientswithsarscov2

Ejemplares similares